McKesson said on August 25, 2024 that it entered into a unit purchase agreement with Florida Cancer Specialists & Research Institute, LLC and Core Ventures to acquire a controlling interest of approximately 70% for approximately $2.49 billion in cash, subject to customary adjustments.

1. 01

   McKesson said on August 25, 2024 that it entered into a unit purchase agreement with Florida Cancer Specialists & Research Institute, LLC and Core Ventures to acquire a controlling interest of approximately 70% for approximately $2.49 billion in cash, subject to customary adjustments.

2. 02

   The company said closing of the transaction is subject to the satisfaction of customary closing conditions, including regulatory review. It also cited the risk that it may be unable to obtain the necessary regulatory approvals.

3. 03

   The company said that after the deal closes, Core Ventures will be part of the Oncology platform and its financial results will be reported in the US Pharmaceutical segment. FCS physicians will continue to hold a minority interest in Core Ventures.

4. 04

   The company said that after closing, FCS will remain independently owned and will join The US Oncology Network. FCS is a medical practice with more than 250 physicians, 280 advanced practice providers and about 100 locations in Florida.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.